THERAPY DOSSIER · th-e7fce72dfd46

Cavidine (alkaloid from Corydalis impatiens)

Drug · Cavidine (alkaloid from Corydalis impatiens); no confident ChEMBL name match returned

Evidence & regulatory context

Mechanism: Cavidine (alkaloid from Corydalis impatiens); no confident ChEMBL name match returned
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27380619 ↗2016Reported benefit

Anti-ulcerogenic effect of cavidine against ethanol-induced acute gastric ulcer in mice and possible underlying mechanism.

MouseChemical/toxinMaleIntragastric1, 5 or 10 mg/kgPre-treatment, 12 h and 1 h before ethanol administration

Model: Acute gastric ulcer induced by intragastric absolute ethanol (0.5 mL/100 g), animals euthanised 3 h after ethanol ingestion

Cavidine pre-treatment reduced macroscopic and histological gastric injury, lowered malondialdehyde, myeloperoxidase, interleukin-6 and tumour necrosis factor alpha, and raised mucosal glutathione, superoxide dismutase and prostaglandin E2 relative to the ethanol model group.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…